SciELO - Scientific Electronic Library Online

 
vol.13 issue5Health locus of control and depressive symptoms among adolescents in Alexandria, EgyptStudy between axillary and rectal temperature measurements in children author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Eastern Mediterranean Health Journal

Print version ISSN 1020-3397

Abstract

GHADER, F.R.; KOUSARIAN, M.  and  FARZIN, D.. High-dose deferoxamine treatment (intravenous) for thalassaemia patients with cardiac complications. East. Mediterr. health j. [online]. 2007, vol.13, n.5, pp. 1053-1059. ISSN 1020-3397.

As a means to manage cardiac conditions, we determined the effects of high-dose intravenous (IV) deferoxamine in 15 thalassaemia patients with cardiomyopathy and high ferritin and haemoglobin levels. The patients received IV deferoxamine, 130 mg/kg per day over 10-14 hours (maximum 5 g) for 5 consecutive days. All patients underwent a full evaluation before receiving deferoxamine, and 2 days and 1 month after completing the treatment. Visual and auditory examinations were done to detect any side-effects. After treatment, cardiovascular symptoms decreased considerably and systolic function showed significant improvement, but there was no significant effect on diastolic function, electro-cardiography and physical findings. There were no significant side-effects reported.

        · abstract in French | Arabic     · text in English     · pdf in English